A digital health solution transforms the inhaler into a connected device

ByLance T. Lee

Feb 9, 2022

Aptar Pharma, a specialist in drug delivery, services and active materials science solutions, has launched HeroTracker Sense, a digital respiratory health solution that transforms a standard metered-dose inhaler (pMDI) into a smart connected health device .

HeroTracker Sense is designed to help improve the lives of patients around the world suffering from chronic respiratory diseases such as asthma, COPD, cystic fibrosis and other respiratory conditions caused by COVID-19, to track their use of metered-dose inhalers and facilitate better adherence to their therapy prescription.

HeroTracker Sense is a smart metered-dose inhaler (MDI) add-on device designed to address patient inhalation technique and compliance.

By attaching to the cartridge of an MDI, HeroTracker Sense has several features to help asthma and COPD patients take their medications in a more informed way. Device sensors enable the creation and delivery of information such as coordination of inspiration with actuation, rate and duration of inhalation. Other features available through the app include timestamps to indicate when the patient should take their medication, as well as environmental monitoring alerts such as temperature and humidity.

HeroTracker Sense provides healthcare providers (HCPs) with valuable patient training, onboarding and performance analytics and insights through the Aptar Pharma Cohero Health BreatheSmart Connect portal, which is both HIPAA compliant and GDPR, while patients can monitor their adherence through the BreatheSmart app.

Sai Shankar, President, Digital Health, Aptar Pharma, said, “HeroTracker Sense is a strategic addition to Aptar’s portfolio of digital health solutions in respiratory, and underscores Aptar Pharma’s advancements in therapeutics. technology, as well as our commitment to providing tools that will lead to improved lives for patients.

Marcus Bates, Director, Business Development, Digital Health, Aptar Pharma, added, “The launch of HeroTracker Sense positions Aptar’s digital respiratory portfolio as a world-leading offering, providing insights into patient behaviors and how that will lead to a change in the way the patient interacts with their device and their understanding of their indication. We see this as a product for the future that will demonstrate significant value, creating concrete evidence that can help support reimbursement models in many different markets.

HeroTracker Sense was designed and developed using Aptar Digital Health’s ISO 13485 certified quality management system, is CE marked and is pending FDA approval.

Source link